TITLE

Lacidipine/lopinavir/ritonavir/metoprolol interaction

PUB. DATE
April 2011
SOURCE
Reactions Weekly;4/16/2011, Issue 1347, p26
SOURCE TYPE
Periodical
DOC. TYPE
Case Study
ABSTRACT
The article describes the case of a 51-year-old man who developed bradycardia, hypotension and complete antrioventricular (AV) block while being treated with lacidipine, lopinavir, ritonavir and metoprolol.
ACCESSION #
60073994

 

Related Articles

  • Antiretrovirals/gemfibrozil/rosuvastatin interaction.  // Reactions Weekly;8/13/2011, Issue 1364, p8 

    The article describes the case of an eldery man who developed rhabdomyolysis during treatment with lopinavir/ritonavir and tenofovir for HIV infection and gemfibrozil and rosuvastatin for dyslipidemia.

  • Lopinavir/ritonavir.  // Reactions Weekly;Nov2014, Vol. 1528 Issue 1, p137 

    The article presents case studies of two HIV-infected patients who developed symptomatic grade III hepatotoxicity after receiving double-dose lopinavir/ ritonavir tablets for at least 2 months.

  • Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers. Jackson, A. G. A.; Hill, A.; Else, L. J.; Back, D. J.; Morley, R.; Puls, R.; Amin, J.; Lin, E.; Boffito, M. // Journal of the International AIDS Society;2010 Supplement 4, Vol. 13 Issue Suppl 4, p1 

    An abstract of the article "Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers," by several authors including AGA Jackson, A Hill, and DJ Back is presented.

  • Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy. Surah, S.; Oshea, S.; Costelloe, S.; Hanlon, M.; Mullen, J.; Chrystie, I.; Taylor, G. P.; De Ruiter, A. // Journal of the International AIDS Society;2010 Supplement 4, Vol. 13 Issue Suppl 4, p1 

    An abstract of the article "Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy," by several authors including GP Taylor, M Douglas, and J Smith is presented.

  • Orlistat/lopinavir/ritonavir interaction.  // Reactions Weekly;5/7/2011, Issue 1350, p36 

    The article describes the case of a 39-year-old woman with HIV-1 infection who experienced decreased cerebrospinal fluid (CSF) lopinavir concentrations, leading to HIV-related meningo-encephalitis, during highly active anti-retroviral therapy (HAART) with lopinavir/ritonavir in addition to...

  • Efavirenz interaction.  // Reactions Weekly;8/26/2006, Issue 1116, p13 

    The article describes the case of a 37-year-old man with acute HIV infection who developed increased serum efavirenz concentrations after receiving efavirenz and decreased plasma lopinavir concentration following an interaction with concomitant lopinavir.

  • Lopinavir/ritonavir.  // Reactions Weekly;8/13/2011, Issue 1364, p31 

    The article describes three cases of premature infants who developed adrenal insufficiency after receiving treatment with lopinavir/ritonavir.

  • TGA approval for HIV drug.  // Australian Journal of Pharmacy;Feb2011, Vol. 92 Issue 1089, p38 

    The article announces that the drug Kaletra (lopinavir/ritonavir) has been approved by the TGA for HIV treatment in combination with other antiretroviral drugs.

  • Lopinavir/ritonavir/tenofovir interaction.  // Reactions Weekly;7/6/2013, Issue 1460, p29 

    The article presents a case study of a man who developed Fanconi syndrome after being treated with lopinavir/ritonavir and tenofovir for HIV infection.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics